An observational study in Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft, sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. Recruiting at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd (part of MicroPort Scientific Corporation) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Aortic Aneurysm, Abdominal with a site in China — 7 open to participants now, 9 under way, none of them phase 3. Aortic Aneurysm, Abdominal · China.
Among the 17 studies in Aortic Aneurysm, Abdominal with a site in China, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 16th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →7 of the 17 studies in Aortic Aneurysm, Abdominal with a site in China are open now. Recruiting first, the newest first:
Medtronic Cardiovascular · Sites in China
Ages 18+
First Affiliated Hospital of Kunming Medical University · Sites in China
Ages 20–90
RenJi Hospital · Sites in China
Ages 50+
RenJi Hospital · Sites in China
Ages 18+
RenJi Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 200 is above the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 113 across the 8 interventional studies, 200 across the 9 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd, one of the names counted as MicroPort Scientific Corporation. Under that name alone:
Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
MicroPort Scientific Corporation has 6 studies filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Aneurysm, Abdominal with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05133492Nectero Medical, Inc.First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA) | 2026-12-31 |
| NCT07039825RenJi HospitalAAA-CTA Cohort Registry | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Aortic Aneurysm, Abdominal with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Minos™ Abdominal Aortic Stent-Graft and Delivery System is a medical device designed to treat abdominal aortic aneurysms using a minimally invasive procedure. The device is placed inside the aorta through blood vessels, usually accessed through small incisions in the groin. The goal of this observational study is to collect short-, medium- to long-term safety and performance data of the Minos™ stent-graft in everyday medical practice (real-world settings). The aim is to study about 200 patients worldwide and at least 30 patients in European hospitals.
Chinese and European subjects suffering abdominal aortic aneurysm with a proximal neck length ≥15mm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects to be treated with Minos™ Abdominal Aortic Stent-Graft and Delivery System who meet the criteria for inclusion in the PEARL study and voluntarily consent to participate.
Device: Implantation with Minos Stent graft
Treatment of subjects diagnosed with abdominal aortic aneurysm using the low-profile Minos Abdominal Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.
Technical success rate at 12 months
Technical success at 12 months is defined as accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery, the absence of aneurysm rupture, continuous type I and III endoleaks after operation, aneurysm enlargement (aneurysm diameter increased by more than 5mm), secondary intervention due to endoleak, stent occlusion or migration, including open surgery and endovascular surgery. Expected secondary interventions will not be included in the analysis.
Time frame: 12 months
Incidence of major adverse events at 30 days
Time frame: 30 days
Immediate technical success
Immediate technical success is measured as successful introduction and withdrawal of stent graft and delivery system, with accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery.
Time frame: within 24 hours post-implantation
Incidence of successful aneurysm treatment at 2-5 years
Successful aneurysm treatment during the follow-up period of 2-5 years is defined as accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery, the absence of aneurysm rupture, continuous type I and III endoleaks after operation, aneurysm enlargement (aneurysm diameter increased by more than 5mm), secondary intervention due to endoleak, stent occlusion or migration, including open surgery and endovascular surgery.
Time frame: Years 2-5 post-implantation
All-cause mortality up to 5 years post-procedure
Time frame: From implantation to the end of follow up at 5 years
Aortic aneurysm related mortality up to 5 years post-procedure
Time frame: From implantation to the end of follow up at 5 years
Secondary intervention rates up to 5 years post-procedure
Secondary intervention rates up to 5 years after TEVAR are measured by tracking all subsequent open and endovascular procedures required to treat device-related or aortic complications. This includes Open surgery: performed at any time to address a failure of endovascular treatment due to failure of stent implantation or placement, complications or other clinical conditions, or after the initial success of endovascular treatment, and Secondary endovascular intervention: any intravascular surgical intervention performed to resolve complications such as endoleak, aneurysm expansion, stent occlusion, stent migration and stent defect after the implantation of Minos™ system.
Time frame: From implantation to the end of follow up at 5 years
Aneurysm diameter and variation in aneurysm diameter from 30 days to 5 years post-procedure
Time frame: From 30 days post-implantation until end of follow up at 5 years
Incidence of type I and type III endoleaks from 30 days to 5 years post-procedure
Time frame: From 30 days post-implantation until end of follow up at 5 years
Incidence rate of stent migration, fracture, stenosis, occlusion and distortion from 30 days to 5 years post-procedure
Time frame: From 30 days post-implantation until end of follow up at 5 years
Plan to share: Yes
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Oct 2028, 67 months after the start.
Of 91 observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 67 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd →